GURUFOCUS.COM » STOCK LIST » USA » NAS » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Cash Flow from Operations
Switch to:

Intercept Pharmaceuticals (NAS:ICPT) Cash Flow from Operations

: $-58.3 Mil (TTM As of Mar. 2023)
View and export this data going back to 2012. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2023, Intercept Pharmaceuticals's Net Income From Continuing Operations was $-31.9 Mil. Its Depreciation, Depletion and Amortization was $0.1 Mil. Its Change In Working Capital was $-24.1 Mil. Its cash flow from deferred tax was $0.0 Mil. Its Cash from Discontinued Operating Activities was $-0.3 Mil. Its Asset Impairment Charge was $0.0 Mil. Its Stock Based Compensation was $5.9 Mil. And its Cash Flow from Others was $-1.3 Mil. In all, Intercept Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2023 was $-51.6 Mil.


Intercept Pharmaceuticals Cash Flow from Operations Historical Data

The historical data trend for Intercept Pharmaceuticals's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -240.71 -236.61 -171.86 -41.07 -26.78

Intercept Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Flow from Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.12 14.74 -16.59 -4.81 -51.60

Intercept Pharmaceuticals Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Intercept Pharmaceuticals's Cash Flow from Operations for the fiscal year that ended in Dec. 2022 is calculated as:

Intercept Pharmaceuticals's Cash Flow from Operations for the quarter that ended in Mar. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intercept Pharmaceuticals  (NAS:ICPT) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Intercept Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2023 was $-31.9 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Intercept Pharmaceuticals's depreciation, depletion and amortization for the three months ended in Mar. 2023 was $0.1 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Intercept Pharmaceuticals's change in working capital for the three months ended in Mar. 2023 was $-24.1 Mil. It means Intercept Pharmaceuticals's working capital declined by $24.1 Mil from Dec. 2022 to Mar. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Intercept Pharmaceuticals's cash flow from deferred tax for the three months ended in Mar. 2023 was $0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Intercept Pharmaceuticals's cash from discontinued operating Activities for the three months ended in Mar. 2023 was $-0.3 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Intercept Pharmaceuticals's asset impairment charge for the three months ended in Mar. 2023 was $0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Intercept Pharmaceuticals's stock based compensation for the three months ended in Mar. 2023 was $5.9 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Intercept Pharmaceuticals's cash flow from others for the three months ended in Mar. 2023 was $-1.3 Mil.


Intercept Pharmaceuticals Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Intercept Pharmaceuticals (NAS:ICPT) Business Description

Intercept Pharmaceuticals logo
Traded in Other Exchanges
Address
10 Hudson Yards, 37th Floor, New York, NY, USA, 10001
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Executives
Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451

Intercept Pharmaceuticals (NAS:ICPT) Headlines

Other Sources